Drugs / glecaprevir/pibrentasvir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03623568 | Feb 2019 → Dec 2020 | hepatitis C virus infection, kidney failure | Raymond T. Chung, MD | Withdrawn | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glecaprevir/pibrentasvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03623568 ↗ |